Biolexis Therapeutics Inc.
Oral small-molecule therapeutics targeting GLP-1 and AMPK pathways for metabolic diseases
- Sector
- Biotech
- Headquarters
- LEHI, UT
- Founded
- 2021
- Latest Form D
- $1.6M, Jun 2026
- Total capital
- $6.3M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $6.3M
- 5 Form D · last Jun 2026
- 5 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 13 pending · first 2025
- Rank in peer group#481 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 5th filing$1.6M
- Private capital raisedForm D · SEC · 4th filing$1M
- Private capital raisedForm D · SEC · 3rd filing$725K
- Private capital raisedForm D · SEC · 2nd filing$1.5M
- Private capital raisedForm D · SEC · 1st filing$1.5M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#481 · top 33%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Hariprasad J. VankayalapatiResearcherDirectorLinked by 1 patent
- Anthony N. SteveDirectorNamed in SEC Form D filings
- David J. BearssExecutive OfficerNamed in SEC Form D filings
- David O. TaylorExecutive OfficerNamed in SEC Form D filings
- Dr. David J. BearssExecutive Officer, DirectorNamed in SEC Form D filings
- Dr. Hariprasad J. VankayalapatiExecutive OfficerNamed in SEC Form D filings
Show all 8 people
- James N. ClarkeDirectorNamed in SEC Form D filings
- Tyler HartmannExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 14- PendingGLP-1 Agonists And Methods Of UseUSPTOApplication 19242622
- PendingAmp-activated Protein Kinase Modulator Compounds And Uses ThereofUSPTOApplication 19242621
- GrantedCDK9 InhibitorsUSPTOUS 12,275,738
Show all 14 patent records
- GLP-1 Agonists And Methods Of UseJun 4, 2026 · Application 19242622Pending
- Amp-activated Protein Kinase Modulator Compounds And Uses ThereofDec 25, 2025 · Application 19242621Pending
- CDK9 InhibitorsApr 15, 2025 · US 12,275,738Granted
- GLP-1 Agonists And Methods Of UseApplication 63662311Pending
- Pim Inhibitors And Method Of Their UseApplication 63654637Pending
- Amp-activated Protein Kinase Modulator Compounds And Uses ThereofApplication PCTUS2025034254Pending
- Bifunctional Protac And Molecular Glue Compounds And Methods Of Use ThereofApplication 63589210Pending
- CDK9 InhibitorsApplication PCTUS2023017760Pending
- CDK9 InhibitorsApplication PCTUS2023017761Pending
- CDK9 InhibitorsApplication 63329139Pending
- CDK9 InhibitorsApplication 63329105Pending
- HDAC6 Inhibitors And Method Of Their UseApplication 63654635Pending
- GLP-1 Agonists And Methods Of UseApplication PCTUS2025034243Pending
- Amp-activated Protein Kinase Modulator Compounds And Uses ThereofApplication 63662310Pending
Related companies, and why
- Cytosolix, Inc.Similar federal contract value in Biotech · null in contracts
- Jellatech, Inc.Similar federal contract value in Biotech · null in contracts
- Moleculin, LLCSimilar federal contract value in Biotech · null in contracts
- Hilltop Biosciences Inc.Similar federal contract value in Biotech · null in contracts
- Boston Bioprocess, Inc.Similar federal contract value in Biotech · null in contracts
- Neo Quantum Era Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .